



Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

SAA Measure Description¹

Assesses adults 18 years of age and older who have schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

Why is SAA Important?¹

Schizophrenia is a chronic and disabling psychiatric disorder that requires ongoing treatment and monitoring. Symptoms include hallucinations, illogical thinking, memory impairment, and incoherent speech. Medication non-adherence is common and a major concern in the treatment of schizophrenia. Using antipsychotic medications as prescribed reduces the risk of relapse or hospitalization.

Best Practices

- ✓ Review pharmacy locations where a patient gets refills and identify transportation needs (if any).
- ✓ Review patients access to prescribed medications and capacity for purchasing/affording medications.
- ✓ Coordinate care between BH provider and PCP requesting test results, communicating test results or scheduling an appointment for testing/screening.
- ✓ Improve medication education by informing patient why they are taking a medication, medication targets, side effects and importance of adherence.
- ✓ Follow up with phone calls to help ensure adherence and to re-evaluate the patient's understanding.

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: <https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/>

² Source: HEDIS MY 2025 Tech Specs Manual Vol. 2

Numerator Compliance²

The number of members who achieved a proportion of days covered of at least 80% for their antipsychotic medications during the measurement year.

Refer to the next page for the list of medications.

Data Collection Method²

Administrative (Claims)



Trillium Percentages/NCQA National Averages¹

| SAA | Measurement Year | Trillium | NCQA National Average |
|-------|------------------|----------|-----------------------|
| Total | 2023 | 63.68 | 61.09 |
| | 2022 | 67.1 | 59.8 |

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: <https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/>

² Source: HEDIS MY 2025 Tech Specs Manual Vol. 2

SAA Numerator Medications²

| Description | Prescription | |
|---|---|---|
| Long-acting injections 14 days supply | Risperidone (excluding Perseris®) | |
| Long-acting injections 28 days supply | Aripiprazole Aripiprazole lauroxil Fluphenazine decanoate | Haloperidol decanoate Olanzapine Paliperidone palmitate |
| Long-acting injections 30 days supply | Risperidone (Perseris®) | |
| Long-acting injections 35 days supply | Paliperidone palmitate (Invega Sustenna) | |
| Long-acting injections 104 days supply | Paliperidone palmitate (Invega Trinza) | |
| Long-acting injections 201 days supply | Paliperidone palmitate (Invega Hafyera) | |
| Miscellaneous antipsychotic agents (oral) | Aripiprazole Asenapine Brexipiprazole Cariprazine Clozapine Haloperidol Iloperidone Loxapine | Lumateperone Lurasidone Molindone Olanzapine Paliperidone Quetiapine Risperidone Ziprasidone |
| Phenothiazine antipsychotics (oral) | Chlorpromazine Fluphenazine Perphenazine | Prochlorperazine Thioridazine Trifluoperazine |
| Psychotherapeutic combinations (oral) | Amitriptyline-perphenazine | |
| Thioxanthenes (oral) | Thiothixene | |

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: <https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/>

² Source: HEDIS MY 2025 Tech Specs Manual Vol. 2